150 billion yuan children's market competition is fierce, and another pharmaceutical enterprise has entered the siege

[pharmaceutical network market analysis] recently, shaoma Zhijing granules, a modern Chinese medicine developed by Tianshi, was approved by the National Drug Administration (nmpa) for marketing (gyzz20190022) to treat Tourette syndrome (Tourette syndrome) and chronic tic disorder It is understood that the new drug shaoma antispasmodic granule approved by Tianshili this time is used for patients over 5 years old Its main ingredients are 11 kinds of traditional Chinese medicines, such as white peony, gastrodia, Tribulus terrestris, uncaria, Ganoderma lucidum, etc., which are worthy of the name In the aspect of functional indications, shaoma Zhijing granule has the functions of calming the liver Yang, calming the wind and stopping the spasm, clearing the fire and eliminating phlegm It is used to treat Tourette syndrome (Tourette syndrome) and chronic Tourette disorder, which belong to the patients with hyperactivity of liver and disturbance of phlegm and fire Relevant person in charge of Tianshili said that the approval of shaoma Zhijing granules marks that Tianshili has entered the field of children's medicine rarely involved in the past through its own research and development innovation, which is an exploration for Tianshili to expand the blue ocean market of children's medicine In fact, there is a shortage of drugs for children in China Compared with adult drug use, the research and development process of children's drug use, especially the clinical trials, is more difficult, and the enthusiasm of drug companies in research and development is generally low, so there is a larger development space for children's drug market According to some data, the market scale of children's drug use only accounts for 5% of the pharmaceutical industry, while the number of children accounts for about 16.6% of the whole country The market of children's drug use is far from saturation In 2013, China's children's drug market exceeded 100 billion yuan, and in 2018, the children's drug market officially exceeded 150 billion yuan In the future, with the continuous liberalization of the two child policy, the market capacity will continue to expand However, in contrast to the huge market demand, children's drug use has been in a "marginal" state for a long time Because children's physiological conditions and metabolic processes of drugs are different from those of adults, the parents of children's drug use mostly rely on their hands, and lack of special drugs for children In recent years, there are not many new products on the market due to the difficulty in the development of pediatric drug products According to the data, among the 3500 kinds of pharmaceutical preparations in China, there are only 60 kinds of special drugs for children, accounting for about 1.7% of the total number of drugs; among more than 6000 pharmaceutical enterprises, there are only 10 pharmaceutical enterprises specialized in the production of children's drugs There are also data showing that about 30000 children in China fall into the silent world every year due to improper use of drugs, causing liver and kidney function, nervous system and other injuries, which is even more difficult to count The proportion of children with drug poisoning in all the children visited has increased from 53% in 2012 to 73% in 2014 Therefore, in order to encourage the research and development of children's drug products, in recent years, the state has given great policy encouragement to children's drug use, no matter in the aspects of review and approval or medical insurance access For example, on August 27, the National Health Commission released the list of the third batch of children's drugs encouraged to develop and declare, including 34 children's drugs with large clinical demand, such as aspirin, diazepam, lidocaine, spironolactone, sildenafil, enalapril, etc The new version of the drug administration law, which was officially implemented on December 1, 2019, also raised the encouragement of children's drug use to the legal level for the first time, making it clear that the state will take effective measures to encourage the development and innovation of children's drugs, support the development of new varieties, dosage forms and specifications of children's drugs that meet the physiological characteristics of children, and give priority to the review and approval of children's drugs Under many favorable policies, relevant pharmaceutical companies are also increasing the layout of drug research and development for children For example, Kangzhi pharmaceutical pointed out in the mid year report that the company will vigorously promote the innovative research platform, devote itself to solving the innovation problems of children's preparations such as reducing drug dosage and improving safety, and develop and produce high-quality new children's drugs In addition, dyne pharmaceutical has developed more than 70 special drugs for children, involving the treatment of common, frequently occurring and some rare diseases for children Recently, China Resources Sanjiu acquired Aonuo pharmaceutical mainly because of its favorable market scale and its well-known brands of children's calcium supplement such as Aonuo, Jinxin jinjute and vitamin C chewable tablets.